Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Speranza, F"'
Autor:
Torre D; Department of Infectious Diseases, General Hospital, Viale Borri 57, 21100 Varese, Italy. donatotorre@libero.it, Speranza F, Ghezzi S, Nozza S, Tambussi G, Soldini L, Dorigatti F, Lazzarin A, Tambini R, Poli G
Publikováno v:
HIV clinical trials [HIV Clin Trials] 2004 May-Jun; Vol. 5 (3), pp. 146-51.
Autor:
Torre D; Department of Infectious Diseases, General Hospital and Macchi Foundation, Varese, Italy. donatotorre@libero.it, Speranza F
Publikováno v:
The Lancet. Infectious diseases [Lancet Infect Dis] 2003 Oct; Vol. 3 (10), pp. 609-10.
Autor:
Torre D; Department of Infectious Diseases, Regional Hospital and Macchi Foundation, Varese, Italy. eiwle@tin.it, Pugliese A, Speranza F
Publikováno v:
The Lancet. Infectious diseases [Lancet Infect Dis] 2002 May; Vol. 2 (5), pp. 273-80.
Autor:
Torre D; Div. of Infectious Diseases, Regional Hospital, Varese, Italy., Zeroli C, Ferrario G, Pugliese A, Speranza F, Orani A, Casari S, Bassi P, Poggio A, Carosi GP, Fiori GP
Publikováno v:
Infection [Infection] 1999 May-Jun; Vol. 27 (3), pp. 218-20.
Autor:
Torre D; Division of Infectious Diseases, Regional Hospital, Varese, Italy., Ferrario G, Speranza F, Martegani R, Zeroli C
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 1996 Apr; Vol. 22 (4), pp. 650-3.
Autor:
Torre D; Division of Infectious Diseases, Regional Hospital, Varese, Italy., Ferrario G, Bonetta G, Perversi L, Speranza F
Publikováno v:
FEMS immunology and medical microbiology [FEMS Immunol Med Microbiol] 1996 Feb; Vol. 13 (2), pp. 95-9.
Publikováno v:
AIDS (London, England) [AIDS] 1995 Aug; Vol. 9 (8), pp. 979-80.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Donato Torre, Silvia Nozza, Filippo Speranza, Adriano Lazzarin, Roberto Tambini, Silvia Ghezzi, Guido Poli, Giuseppe Tambussi, Fernanda Dorigatti, Laura Soldini
Publikováno v:
HIV Clinical Trials. 5:146-151
Background: Interleukin-2 (IL-2) has been investigated as an adjunct to antiretroviral therapy (ART) because of its well-demonstrated capacity of stably increasing the number of peripheral CD4+ T cell lymphocytes. However, IL-2-related adverse events